OBJECTIVES: To better understand indications for β-blocker (BB) prescriptions among older adults hospitalized with heart failure with preserved ejection fraction (HFpEF). DESIGN/ SETTING: Retrospective observational study of hospitalizations derived from the geographically diverse Reasons for Geographic and Racial Differences in Stroke cohort. PARTICIPANTS: We examined Medicare beneficiaries aged 65 years or older with an expert-adjudicated hospitalization for HFpEF (left ventricular ejection fraction = 50% or greater). MEASUREMENTS: Discharge medications and indications for BBs were abstracted from medical records. RESULTS: Of 306 hospitalizations for HFpEF, BBs were prescribed at discharge in 68%. Among hospitalizations resulting in BB prescriptions, 60% had a compelling indication for BB-44% had arrhythmias, and 29% had myocardial infarction (MI) history. Among the 40% with neither indication, 57% had coronary artery disease (CAD) without MI and 38% had hypertension alone (without arrhythmia, MI, or CAD), both clinical scenarios with little supportive evidence of benefit of BBs. Among hospitalizations resulting in BB prescription at discharge, 69% had geriatric conditions (functional limitation, cognitive impairment, hypoalbuminemia, or history of falls). There were no significant differences in the prevalence of geriatric conditions between hospitalizations of individuals with compelling indications for BBs and hospitalizations of individuals with noncompelling indications. CONCLUSIONS: BBs are commonly prescribed following a hospitalization for HFpEF, even in the absence of compelling indications. This occurs even for hospitalizations of individuals with geriatric conditions, a subpopulation who may be at elevated risk for experiencing harm from BBs.
OBJECTIVES: To better understand indications for β-blocker (BB) prescriptions among older adults hospitalized with heart failure with preserved ejection fraction (HFpEF). DESIGN/ SETTING: Retrospective observational study of hospitalizations derived from the geographically diverse Reasons for Geographic and Racial Differences in Stroke cohort. PARTICIPANTS: We examined Medicare beneficiaries aged 65 years or older with an expert-adjudicated hospitalization for HFpEF (left ventricular ejection fraction = 50% or greater). MEASUREMENTS: Discharge medications and indications for BBs were abstracted from medical records. RESULTS: Of 306 hospitalizations for HFpEF, BBs were prescribed at discharge in 68%. Among hospitalizations resulting in BB prescriptions, 60% had a compelling indication for BB-44% had arrhythmias, and 29% had myocardial infarction (MI) history. Among the 40% with neither indication, 57% had coronary artery disease (CAD) without MI and 38% had hypertension alone (without arrhythmia, MI, or CAD), both clinical scenarios with little supportive evidence of benefit of BBs. Among hospitalizations resulting in BB prescription at discharge, 69% had geriatric conditions (functional limitation, cognitive impairment, hypoalbuminemia, or history of falls). There were no significant differences in the prevalence of geriatric conditions between hospitalizations of individuals with compelling indications for BBs and hospitalizations of individuals with noncompelling indications. CONCLUSIONS: BBs are commonly prescribed following a hospitalization for HFpEF, even in the absence of compelling indications. This occurs even for hospitalizations of individuals with geriatric conditions, a subpopulation who may be at elevated risk for experiencing harm from BBs.
Authors: Viviane M Conraads; Marco Metra; Otto Kamp; Gilles W De Keulenaer; Burkert Pieske; José Zamorano; Panos E Vardas; Michael Böhm; Livio Dei Cas Journal: Eur J Heart Fail Date: 2011-12-06 Impact factor: 15.534
Authors: Virginia J Howard; Mary Cushman; Leavonne Pulley; Camilo R Gomez; Rodney C Go; Ronald J Prineas; Andra Graham; Claudia S Moy; George Howard Journal: Neuroepidemiology Date: 2005-06-29 Impact factor: 3.282
Authors: Fabrizia Lattanzio; Irma Laino; Claudio Pedone; Francesco Corica; Giuseppe Maltese; Giovanni Salerno; Sabrina Garasto; Andrea Corsonello; Raffaele Antonelli Incalzi Journal: J Am Med Dir Assoc Date: 2011-05-31 Impact factor: 4.669
Authors: Barry A Borlaug; Vojtech Melenovsky; Stuart D Russell; Kristy Kessler; Karel Pacak; Lewis C Becker; David A Kass Journal: Circulation Date: 2006-11-06 Impact factor: 29.690
Authors: Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren Journal: Lancet Date: 2003-09-06 Impact factor: 79.321
Authors: Christopher M Callahan; Frederick W Unverzagt; Siu L Hui; Anthony J Perkins; Hugh C Hendrie Journal: Med Care Date: 2002-09 Impact factor: 2.983
Authors: Barry M Massie; Peter E Carson; John J McMurray; Michel Komajda; Robert McKelvie; Michael R Zile; Susan Anderson; Mark Donovan; Erik Iverson; Christoph Staiger; Agata Ptaszynska Journal: N Engl J Med Date: 2008-11-11 Impact factor: 91.245
Authors: Parag Goyal; Tatiana Requijo; Birgit Siceloff; Megan J Shen; Ruth Masterson Creber; Sarah N Hilmer; Ian M Kronish; Mark S Lachs; Monika M Safford Journal: Drugs Aging Date: 2020-02 Impact factor: 3.923
Authors: Parag Goyal; Monika M Safford; Sarah N Hilmer; Michael A Steinman; Daniel D Matlock; Mathew S Maurer; Mark S Lachs; Ian M Kronish Journal: Br J Clin Pharmacol Date: 2022-07-13 Impact factor: 3.716
Authors: Lina M Brinker; Matthew C Konerman; Pedram Navid; Michael P Dorsch; Jennifer McNamara; Cristen J Willer; Mary E Tinetti; Scott L Hummel; Parag Goyal Journal: Am J Med Date: 2020-08-18 Impact factor: 4.965